NVSNovartis PharmaceuticalsRunning, no new patients
Ribociclib (LEE011) Rollover Study for Continued Access
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 22 (final count)
- Started
- Dec 15, 2016
- Main results expected
- Feb 1, 2027
- Fully finished
- Feb 1, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Patients enrolled and received LEE011
Measured over: up to 5 years (study duration)
Length of time receiving study treatment
Measured over: up to 5 years (study duration)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02934568 · record last updated 2026-04-16 · checked 2026-11-09 15:47 UTC